This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Prevenar 13, 13–valent pneumococcal conjugate vaccine (Diphtheria CRM197 Protein), 13vPnC, PCV13, Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]
Description: Prevnar-13 is an updated version of the pneumococcal vaccine Prevnar, the first pneumococcal conjugate vaccine licensed in the United States (U.S.). Compared to Prevenar, Prevnar-13 provides coverage against a broader range of pneumococcal serotypes, some of which became important causes of disease only after the near elimination from Western populations of the serotypes covered by the original Prevnar vaccine.Prevnar was approved by the FDA for active immunization to prevent invasive pneumococcal disease (IPD) in February 2000. The active immunogens in Prevnar are capsular polysaccharides derived from seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) conjugated to diphtheria CRM197 protein.
By 2007, in children aged < 5 years, rates of IPD caused by serotypes contained in Prevnar declined by 99%. Although the overall rate of IPD caused by all pneumococcal serotypes was 76% lower in 2007 compared with the years preceding Prevnar introduction, overall IPD rates began to level off in 2002. This leveling off was due to an increase in the incidence of IPD caused by non-Prevnar serotypes, particularly serotype 19A. The six additional pneumococcal serotypes (1,3,5,6A, 7F, and 19A)contained in Prevnar-13 were responsible for approximately 62% of IPD cases in children < 5 years of age in 2007. In this same age group, the thirteen serotypes contained in Prevnar-13 were responsible for approximately 64% of IPD cases in 2007.
Beginning in 2013, Pfizer began reporting Prevnar and Prevnar 13 revenue together under Prevnar Family. The Company also stated that many markets have transitioned from the use of Prevnar/Prevenar (7-valent) to Prevnar 13/Prevenar 13, generally resulting in a lower revenue trend for Prevnar/Prevenar (7-valent). Based on this information we are recording Prevnar family revenue under this drug profile. To go to the seperate Prevnar drug page, click here.
Prevnar 13 was originally developed by Wyeth.
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Pfizer and Takeda
In June 2012, Takeda and Pfizer announced that they have concluded an agreement that, as of...See full deal structure in Biomedtracker
Prevnar 13 News
Additional information available to subscribers only: